Data gathered: July 9
Alternative Data for PTC Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 27 | Sign up | Sign up | Sign up |
| Sentiment | 84 | Sign up | Sign up | Sign up |
| Webpage traffic | 18,000 | Sign up | Sign up | Sign up |
| Employee Rating | 80 | Sign up | Sign up | Sign up |
| Google Trends | 14 | Sign up | Sign up | Sign up |
| Patents | 125 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 7 | Sign up | Sign up | Sign up |
| Facebook Followers | 5,825 | Sign up | Sign up | Sign up |
| Instagram Followers | 3,670 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 4,227 | Sign up | Sign up | Sign up |
| Twitter Followers | 2,328 | Sign up | Sign up | Sign up |
| Twitter Mentions | N/A | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 59 | Sign up | Sign up | Sign up |
| Linkedin Employees | 1,166 | Sign up | Sign up | Sign up |
About PTC Therapeutics
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders.
| Price | $47.65 |
| Target Price | Sign up |
| Volume | 1,210,000 |
| Market Cap | $3.78B |
| Year Range | $36.19 - $57.17 |
| Dividend Yield | 0% |
| PE Ratio | 7.32 |
| Analyst Rating | 50% buy |
| Industry | Biotechnology |
In the news
 |
Vontobel Holding Ltd. Has $553,000 Stake in PTC Therapeutics, Inc. (NASDAQ:PTCT)July 7 - ETF Daily News |
|
Cantor Fitzgerald Has Weak Estimate for PTCT FY2026 EarningsJuly 3 - ETF Daily News |
|
FY2025 EPS Estimate for PTC Therapeutics Reduced by AnalystJuly 2 - ETF Daily News |
|
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Purchased by Diversified Trust CoJune 30 - ETF Daily News |
|
PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Consensus Recommendation of “Moderate Buy” from BrokeragesJune 27 - ETF Daily News |
PTCT Investors Have Opportunity to Join PTC Therapeutics, Inc. Fraud Investigation with the Schall Law FirmJune 23 - Finnhub |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 1.18B | 13M | 1.16B | 867M | 970M | 10.040 |
| Q4 '24 | 213M | 16M | 194M | -66M | -47M | -0.342 |
| Q3 '24 | 197M | 11M | 186M | -107M | -55M | -1.390 |
| Q2 '24 | 187M | 18M | 168M | -99M | -35M | -1.270 |
| Q1 '24 | 210M | 66M | 144M | -92M | 12M | -1.200 |
Insider Transactions View All
| Boulding Mark Elliott filed to sell 103,901 shares at $46. May 19 '25 |
| Boulding Mark Elliott filed to sell 103,901 shares at $46.2. May 19 '25 |
| Klein Matthew B. filed to sell 273,234 shares at $48.7. April 24 '25 |
| Golden Lee Scott filed to sell 75,997 shares at $47. April 4 '25 |
| Pauwels Eric filed to sell 72,640 shares at $58.3. March 18 '25 |
Similar companies
Read more about PTC Therapeutics (PTCT) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of PTC Therapeutics?
The Market Cap of PTC Therapeutics is $3.78B.
What is PTC Therapeutics' PE Ratio?
As of today, PTC Therapeutics' PE (Price to Earnings) ratio is 7.32.
What is the current stock price of PTC Therapeutics?
Currently, the price of one share of PTC Therapeutics stock is $47.65.
How can I analyze the PTCT stock price chart for investment decisions?
The PTCT stock price chart above provides a comprehensive visual representation of PTC Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling PTC Therapeutics shares. Our platform offers an up-to-date PTCT stock price chart, along with technical data analysis and alternative data insights.
Does PTCT offer dividends to its shareholders?
As of our latest update, PTC Therapeutics (PTCT) does not offer dividends to its shareholders. Investors interested in PTC Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of PTC Therapeutics?
Some of the similar stocks of PTC Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.